Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 29 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

0 of 14 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

15(62.5%)

Early Phase 1

3(12.5%)

Phase 3

2(8.3%)

Phase 1

2(8.3%)

Phase 2

1(4.2%)

Phase 4

1(4.2%)

24Total

N/A(15)

Early Phase 1(3)

Phase 3(2)

Phase 1(2)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials

NCT06975943Not ApplicableCompleted

Comparison in Cervical Length and Prolongation of Gestation Age on Vaginal Progesterone Administration to Pregnant Women After the Acute Phase of Threatened Preterm Birth

Role: lead

NCT06935630Not ApplicableCompleted

Comparison of The Effect of 5-MTHF and Folic Acid Supplementation in Increasing Red Blood Cell Folate in Pregnant Women

Role: lead

NCT07328113Completed

Interleukin-6 and Thyroid Dysfunction in Hemodialysis Patients

Role: lead

NCT07298304Not ApplicableCompleted

Impact of Sorghum Rice on Beta-Cell Function and Insulin Resistance in Prediabetes

Role: lead

NCT07266961Not ApplicableCompleted

Low-BFR vs Moderate-Intensity Resistance Training on Cardiorespiratory Fitness in Elderly Women

Role: lead

NCT03775460Not ApplicableActive Not Recruiting

Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum

Role: collaborator

NCT07134595Not ApplicableRecruiting

Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) With Modified-CAPD (M-CAPD) Prescription in Children With End-stage Kidney Disease From Low-resource Settings

Role: collaborator

NCT06553417Not ApplicableCompleted

Emollient 'Plus' vs Urea 10% for Mild-Moderate Atopic Dermatitis

Role: lead

NCT06282692Phase 3Recruiting

INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old

Role: lead

NCT06272253Early Phase 1Active Not Recruiting

UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects

Role: lead

NCT06259578Early Phase 1Recruiting

UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)

Role: lead

NCT06139679Completed

Improvement In Left Ventricular Diameter After Closure Of ASD With Fenestrated Patch: A Cross-sectional Study

Role: lead

NCT05918939Early Phase 1Unknown

UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)

Role: lead

NCT05226429Phase 1Unknown

UNAIR Inactivated COVID-19 Vaccine

Role: lead

NCT05652556Unknown

Quinolone Resistance Profiles and Mechanisms of Staphylococcus Aureus and Escherichia Coli From Humans, Chicken and Catfish Farms in Indonesia

Role: collaborator

NCT05124340Phase 2Completed

Safety and Tuberculin Conversion Following BCG Vaccination

Role: collaborator

NCT05508477Phase 3Unknown

UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)

Role: lead

NCT05465499Completed

Preliminary Survey in Preparation for the Implementation of ERAS at Dr Soetomo Hospital

Role: lead

NCT05254249Phase 1Unknown

Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris

Role: lead

NCT05246124Not ApplicableCompleted

The Effect of Demographic, Mental, and Physical Activity Profiles Towards Burnout in Frontline Healthcare Workers Facing COVID-19 Pandemics in Dr. Soetomo General Hospital Surabaya

Role: lead